Reported results
- Revenue was $492 million in the third quarter of 2026, compared to $504 million in the third quarter of 2025.
- GAAP Operating Loss was $(82) million in the third quarter of 2026, compared to $(109) million in the third quarter of 2025.
- Non-GAAP Adjusted Operating Income was $89 million in the third quarter of 2026, compared to $74 million in the third quarter of 2025.
- GAAP Diluted EPS was $(0.08) and Non-GAAP Adjusted Diluted EPS was $0.11 for the third quarter of 2026.
- GAAP Gross Margin was 53% and Non-GAAP Adjusted Gross Margin was 64% for the third quarter of 2026.
Guidance
- Full-year 2026 revenue guidance range is $1,995 million to $2,020 million.
- Full-year 2026 Operating Loss (GAAP) guidance range is $(4,127) million to $(4,087) million.
- Full-year 2026 Adjusted Operating Income (Non-GAAP) guidance range is $380 million to $420 million.
Notes
The company recognized a benefit from the Israeli Law for the Encouragement and Incentivization of Research and Development (R&D Law) of $52 million in GAAP Operating Income and $51 million in non-GAAP Operating Income during Q3 2026.
Price and volatility reaction
The stock moved -9.2% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -26.4 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 7.06 | 2026-10-28 |
| Close after release | 6.41 | 2026-10-29 |
| Realised move | -9.2% | close to close |
| 30d ATM IV change | -26.4 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.
